SF376 expands Minnesota’s consumer product safety restrictions, with a particular focus on menstrual products. The bill amends existing law on “covered products” to continue prohibiting the import, manufacture, sale, or distribution of covered products containing lead above 90 parts per million or cadmium above 75 parts per million, and it adds menstrual products to the covered-product list. It also authorizes the Pollution Control Agency to adopt future rules identifying additional product categories containing lead, with effective dates no earlier than January 1, 2027 and no later than January 1, 2032.
The bill creates a new section specifically banning menstrual products containing arsenic or “chemicals of high concern,” as defined in Minnesota law. It requires manufacturers to notify sellers and state officials when prohibited menstrual products are identified, and it allows the Pollution Control Agency, Commerce, Health, and the Attorney General to coordinate enforcement. The bill also requires manufacturers of menstrual products with intentionally added synthetic ingredients to disclose those ingredients on the label, and it establishes a testing-and-certification process when regulators suspect a product contains lead, arsenic, or a chemical of high concern. Manufacturers may be required to provide test results, certificates of compliance, and other relevant information, and agencies may charge fees by rule to cover implementation costs.
In practical terms, the bill would affect manufacturers, distributors, and retailers of menstrual products and other consumer goods sold in Minnesota by imposing stricter chemical-content limits, labeling obligations, and potential testing documentation requirements. It also expands agency rulemaking authority and enforcement tools, including joint rules by multiple agencies and the ability to enforce federal restrictions where allowed. The bill would likely require product reformulation, supply-chain review, and compliance monitoring for affected businesses.
The overall sentiment reflected in the bill text and available context appears to be consumer-protection oriented and precautionary, with the bill framed around safety, environmental harm, and transparency. There are no committee transcripts or recorded votes provided, so there is no direct evidence of support or opposition from debate or roll call history. Based on the bill’s structure, it appears designed to strengthen oversight of potentially toxic substances in products used by consumers, especially menstrual products.
Notable points of contention likely center on the breadth of the new prohibitions and the regulatory burden on manufacturers. The bill reaches beyond lead and cadmium to ban menstrual products containing arsenic or any chemical of high concern, and it gives agencies authority to identify additional restricted product categories by rule. Businesses may view the labeling, testing, notification, and fee provisions as costly or administratively complex, while consumer and public-health advocates would likely support the added protections and disclosure requirements.
The bill amends Minnesota Statutes section 325E.3892 to add menstrual products to the list of covered products subject to lead and cadmium limits, and it creates new statutory sections in chapter 325E governing menstrual products containing arsenic or chemicals of high concern. It also expands the Pollution Control Agency’s rulemaking authority to restrict additional product categories containing lead, arsenic, or chemicals of high concern, and it authorizes joint enforcement and rulemaking by the Pollution Control Agency, Commerce, and Health, with Attorney General enforcement support. Manufacturers and sellers of menstrual products would face new labeling, testing, certification, notification, and potential fee requirements.
The bill’s apparent sentiment is strongly consumer-safety focused, emphasizing prevention of exposure to toxic substances and greater transparency in product ingredients. Because no committee transcript or vote record is provided, there is no documented floor or committee debate to indicate partisan or stakeholder alignment. The available text suggests a precautionary approach that would likely be viewed favorably by public-health and consumer advocates, while potentially drawing concern from manufacturers and retailers over compliance costs and regulatory scope.
The main areas of likely contention are the scope of the chemical bans, the inclusion of “chemicals of high concern” in menstrual products, and the extent of agency authority to add more restricted product categories by rule. Manufacturers may object to mandatory testing, certification, ingredient disclosure, notification duties, and fees, especially if compliance requires reformulation or supply-chain changes. Supporters are likely to argue that these measures are necessary to protect consumers, particularly users of menstrual products, from exposure to harmful substances and to improve transparency in the marketplace.